Physiomics inks collaboration deal with ValiRx subsidiary

Physiomics announced on Wednesday that it has signed a collaborative services agreement with Inaphaea BioLabs - a wholly-owned subsidiary of ValiRx.

The AIM-traded firm said the agreement recognised the “complementary nature” of Inaphaea's in-vitro laboratory-based services and Physiomics' in-silico capabilities, including advanced statistical analyses, machine learning techniques, data handling and visualisation, as well as biological modelling.

It said the agreement would allow service users of Inaphaea to access Physiomics' capabilities under a single service contract with Inaphaea.

The integration of data generation and interpretation was expected to benefit both companies and service users.

“The collaborative service agreement will expand the scope of our core consulting business to discovery stage projects and improve our access to clients focused on earlier stages of drug development, while at the same time supporting Inaphaea's own service offering,” said Physiomics chief executive officer Dr Jim Millen.

“The synergy is clear and both the scientific and commercial ambitions of our two companies are well matched.

“We look forward to working closely with ValiRx through this initiative.”

Reporting by Josh White for Sharecast.com.